ETEge Sinan Torun

Ege Sinan Torun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ege Sinan Torun has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Ahmet Gül

    Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    4 shared publications
  • Yasemin Yalçınkaya

    Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    3 shared publications
  • Elif Ertaş

    Department of Biostatistics and Medical Informatics, Atlas University, Faculty of Medicine, Istanbul, Turkey

    2 shared publications
  • Murat Inanç

    Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    2 shared publications
  • Murat İnAnç

    Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    2 shared publications
  • Sabahattin Kaymakoğlu

    Division of Gastroenterohepatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    2 shared publications

Latest Publications

  • Open Access

    Eosinophilic Granulomatosis with Polyangiitis Cases Associated with Leukotriene Receptor Antagonist Use with a Focus on Drug Type, Temporal Drug–Disease Relationship, Steroid-Tapering Status, and Antineutrophil Cytoplasmic Antibody Positivity: A Systemati

    by Ege Sinan Torun, Selin Çelen, Elif Ertaş

    Background/Aims: Eosinophilic granulomatosis with polyangiitis (EGPA) cases associated with leukotriene receptor antagonist (LTRA) use in asthmatic patients are well recognized. We reviewed LTRA-associated EGPA cases, focusing on LTRA types, drug–disease association patterns, steroidtapering status, and antineutrophil cytoplasmic antibody (ANCA) status. Materials and Methods: A systematic literature search was conducted to identify LTRA-associated EGPA cases. Cases were classified according to LTRA type, categorization according to the LTRA-EGPA temporal relationship (as outlined in Masi–Hamilos's article), systemic and/or steroid-tapering status for asthma, and ANCA positivity. Logistic regression analyses were used to determine whether specific clinical features were more common in specific subgroups. Results: Ninety-five patients were identified. Montelukast was used in 65 cases, zafirlukast in 19, and pranlukast in 11. Masi–Hamilos categories: 60 patients in category A, 19 patients in category B, 11 patients in category C, and 5 patients in category D. Twenty-four patients received no steroids prior to EGPA diagnosis, 47 patients received a stable dose of oral and/ or inhaled steroids, and 24 patients had undergone tapering of oral and/ or inhaled steroids before EGPA onset. Of 80 patients with ANCA testing, 32 were ANCA positive. Logistic regression analyses demonstrated higher probabilities of pulmonary infiltrates and cardiomyopathy in EGPA cases associated with zafirlukast use, and an increased probability of sinusitis in Masi–Hamilos C and D categories. Conclusion: While certain clinical features of LTRA-associated EGPA varied across LTRA types and Masi–Hamilos categories, the rarity of cases and the low quality of evidence preclude us from reaching widespread conclusions. Cite this article as: Torun ES, Çelen S, Ertaş E. Eosinophilic Granulomatosis with Polyangiitis Cases Associated with Leukotriene Receptor Antagonist Use with a Focus on Drug Type, Temporal Drug–Disease Relationship, Steroid-Tapering Status, and Antineutrophil Cytoplasmic Antibody Positivity: A Systematic Literature Review. ArchRheumatol. Published online September 17, 2026. doi: 10.5152/ArchRheumatol.2026.26305.

  • Open Access

    Thrombotic microangiopathy in patients with systemic vasculitis: a systematic literature review

    by Ege Sinan Torun, Selin Çelen

    Thrombotic microangiopathy in patients with systemic vasculitis: a systematic literature review - Journal of Turkish Society for Rheumatology

  • Open Access

    Effect of MEFV gene variants and treatment modalities on attack-free period acute phase reactants of patients with familial Mediterranean fever

    by Ege Sinan Torun, Duygu Birinci, Ezgi Fındık, Elif Ertaş

    Effect of MEFV gene variants and treatment modalities on attack-free period acute phase reactants of patients with familial Mediterranean fever - Journal of Turkish Society for Rheumatology

  • Use of Biologic Therapy in AA Amyloidosis Patients Undergoing Dialysis—A Systematic Literature Review

    by Ege Sinan Torun, Gülay Kadıoğlu

    Background: The advent of biological agents has provided significant therapeutic opportunities for patients with AA amyloidosis. However, when these patients reach end‐stage renal disease and begin dialysis, some clinicians may discontinue biological treatments due to the heightened risk of infections. Given that AA amyloidosis is a progressive condition, there is a potential for the disease to affect additional organs in these patients. Consequently, we aimed to evaluate the benefits and risks associated with biological agents in AA amyloidosis patients receiving dialysis. Method: We performed a systematic literature review in Cochrane Database and MEDLINE about the use of biologic agents in AA amyloidosis patients undergoing dialysis. Results: We identified fifty‐five patients across twenty‐two studies. Familial Mediterranean fever was the etiology in 21 patients (71.4% anakinra and 28.6% canakinumab), rheumatoid arthritis in 17 patients (52.9% etanercept and 47.1% tocilizumab), unknown etiology in 8 patients (62.5% anakinra and 37.5% tocilizumab), ankylosing spondylitis in 5 patients (40% etanercept, 40% adalimumab, and 20% infliximab), hidradenitis suppurativa in 3 patients and tumor necrosis factor receptor‐associated periodic syndrome (TRAPS) in 1 patient. Biologic agents were effective or partially effective for primary disease control in 52 patients (94.5%). Two patients were able to discontinue dialysis. Most frequent side effects were infections (8 episodes in 7 patients). Eight patients died (5 due to infections, one due to cardiac causes and two due to pulmonary hemorrhage). Conclusion: Biologic agents are effective in AA amyloidosis patients that are treated with dialysis and seem to have an acceptable safety profile.


  • Budd Chiari syndrome associated with antiphospholipid syndrome: Clinical characteristics and prognosis of 17 patients from single center

    by Ömer Uludağ, Akın Işık, Ege Sinan Torun, Burak Alkaç, Yasemin Yalçınkaya, Ahmet Gül, Murat İnAnç, Sabahattin Kaymakoğlu, Bahar Artim-Esen

    Background and Aim: In this retrospective, descriptive study, we aimed to identify clinical and laboratory characteristics, and prognoses of patients with Budd-Chiari syndrome (BCS) secondary to antiphospholipid syndrome (APS) and to compare with non-BCS vascular thrombotic APS patients. Methods: Data of 194 patients with thrombotic APS (17 with BCS) ± systemic lupus erythematosus (SLE) in a single center between 1982 and 2023 were evaluated. Antiphospholipid serology consisting of lupus anticoagulant (LA), anticardiolipin (aCL) IgG/IgM, anti-beta2 glycoprotein I (aβ2GPI) IgG/IgM and adjusted global APS score (aGAPSS) were evaluated to determine thrombotic risk. Damage was identified for all patients by applying the damage index for APS (DIAPS). All patients with BCS were screened for hereditary or acquired prothrombotic disorders. Results: Patients with BCS had higher aGAPSS and recurrent thrombosis (70.6% vs 40.7%) compared to those with non-BCS. BCS was the first thrombotic event in eight patients and three had recurrent thrombosis. The most common presenting manifestation of BCS was abdominal pain which was followed by abdominal distention and fever. The second prothrombotic factor was detected in six patients: three had heterozygous factor V Leiden mutation, three were in pregnancy period. Additionaly, two patients had SLE flare. The DIAPS of the patients in the BCS and non-BCS groups were similar, but those in the BCS group had higher mortality rates. Conclusions: APS patients with BCS may have a higher risk of recurrent thrombosis and mortality. Acquired or hereditary prothrombotic disorders are not uncommon in this group and should be screened in APS patients with BCS.


  • Open Access

    Role of Positron Emission Tomography-Computed Tomography Scan in Reaching Definite Diagnosis in Patients With Fever of Unknown Origin and Inflammation of Unknown Origin in Rheumatology Outpatient Clinic

    by Umut Yılmaz Koreli, Ege Sinan Torun, Mine Adaş

    Introduction: Patients with fever of unknown origin (FUO) and/or inflammation of unknown origin (IUO) challenge clinicians in daily rheumatology practice. Positron emission tomography-computed tomography (PET/CT) is being used in the diagnostic workup of patients with FUO and/or IUO. This study aims to evaluate the clinical utility and diagnostic performance of PET/CT in the rheumatology outpatient clinic among FUO and IUO patients. Methods: Patients admitted to Prof. Dr. Cemil Taşcıoğlu City Hospital Internal Medicine Rheumatology Outpatient Clinic between February 2022 and September 2023 with FUO and/or IUO and for whom PET/CT scan was performed were included. Initial acute phase reactants, PET/CT results, definite diagnosis and follow-up of patients without a definite diagnosis were retrospectively evaluated. Results: Thirty patients were included. Fifteen patients received a final diagnosis. Diagnoses were ankylosing spondylitis (n=4), rheumatoid arthritis (n=1), systemic lupus erythematosus (n=3), giant cell arteritis (n=1), adult onset Still disease (n=1), undifferentiated connective tissue disease (n=1), undifferentiated vasculitis (n=1) and crystal arthropathy (n=1), Hodgkin lymphoma (n=1) and cryptococcosis (n=1). PET/CT’s diagnostic accuracy was 66.7%, sensitivity was 100% but specificity was 33%. In 15 patients a definite diagnosis was not reached but in most of these patients, fever did not recur and acute phase reactants regressed either spontaneously or with empiric treatment. Discussion: PET/CT reliably helps 50% FUO/IUO patients in receiving definite diagnosis. PET/CT’s high sensitivity implies that negative results can reliably exclude malignancies in most cases. However, due to its low specificity, positive test may not always imply a serious underlying condition. Majority of the definite diagnoses were rheumatic diseases with a very low proportion of infections and malignancies. This is mainly due to the detailed initial evaluations that are performed in internal medicine clinics. Future studies with more patients will better define the role of PET/CT in FUO/IUO patients in rheumatology clinics.


  • Open Access

    The Emerging Targeted Treatments for Giant Cell Arteritis: Beyond Interleukin-6 Inhibition- A Systematic Literature Review

    by Ege Sinan Torun

    Giant cell arteritis is a type of granulomatous vasculitis that primarily affects the large vessels, particularly the aortic arch and its main and distal branches, in individuals over the age of 50. The treatment of this condition usually necessitates the use of steroid-sparing agents. Among the traditional immunosuppressive medications, methotrexate is the most commonly used, and some research also indicates that leflunomide may be effective. With the introduction of biologic therapies, new treatment options have become available for managing giant cell arteritis. Although the results with tumor necrosis factor alpha inhibitors have been underwhelming in this condition, the inhibition of interleukin 6 through tocilizumab has proven to be a safe and effective treatment choice for giant cell arteritis. This systematic literature review seeks to compile and evaluate all existing clinical evidence regarding the efficacy and safety of biologic disease-modifying antirheumatic drugs that operate through mechanisms other than tumor necrosis factor alpha and interleukin-6 inhibition (including costimulation modulation, interleukin-1 inhibition, interleukin 12/23 inhibition, interleukin 17 inhibition, interleukin 23 inhibition, granulocyte-monocyte colony-stimulating factor inhibition, and B cell depletion) as well as targeted synthetic disease-modifying antirheumatic drugs, such as Janus kinase inhibitors, in patients diagnosed with giant cell arteritis.

  • Performances of different classification criteria for systemic lupus erythematosus in a single-center cohort from Turkey

    by Ege Sinan Torun, Erdem Bektaş, Fatih Kemik, Murat Bektaş, Çiğdem Çetin, Yasemin Yalçinkaya, Bahar Artim Esen, Ahmet Gül, Murat Inanç

    Objective: Sensitivity and specificity of SLE classification criteria may vary in different populations and clinical settings. In this study, we aimed to compare the performances of three criteria sets/rules (1997, 2012, and 2019) in a large cohort of patients and relevant diseased controls. Methods: The medical records of consecutive SLE patients and diseased controls were reviewed for clinical and laboratory features relevant to all sets of criteria. Criteria sets/rules were analyzed based on sensitivity, positive predictive value, specificity, and negative predictive value, using clinical diagnosis with at least 6 months of follow-up as the gold standard. A subgroup analysis was performed in ANA positive patients. Results: A total of 393 SLE patients and 308 non-SLE diseased controls were included. Sensitivity was 78.4% for 1997 criteria and was more than 90% for both 2012 (91.9%) and 2019 (94.4%) criteria. Specificity was the highest (95.1%) for 1997 ACR criteria, 91.5% for 2012 SLICC criteria and 91.2% for 2019 EULAR/ACR criteria. When only ANA positive patients were analyzed, sensitivity of each criteria increased by 1%, 0.8%, and 2.2%, respectively. Specificity of 1997 criteria decreased by 2% and specificity of 2012 and 2019 criteria both decreased to less than 90%. Conclusion: EULAR/ACR criteria were more sensitive than 1997 criteria and had a comparable performance with SLICC criteria. When only ANA positive patients were analyzed, the presence of false positive results (originated from patients with Sjögren’s disease and antiphospholipid syndrome mainly) decreased the specificity of both SLICC and EULAR/ACR criteria.